AR069509A1 - PIRIDO (3,2-E) PIRAZINAS, ITS PREPARATION AND USE PROCEDURE AS PHOSPHODESTERASE INHIBITORS 10 - Google Patents
PIRIDO (3,2-E) PIRAZINAS, ITS PREPARATION AND USE PROCEDURE AS PHOSPHODESTERASE INHIBITORS 10Info
- Publication number
- AR069509A1 AR069509A1 ARP080105222A ARP080105222A AR069509A1 AR 069509 A1 AR069509 A1 AR 069509A1 AR P080105222 A ARP080105222 A AR P080105222A AR P080105222 A ARP080105222 A AR P080105222A AR 069509 A1 AR069509 A1 AR 069509A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- polysubstituted
- optionally monosubstituted
- heteroarylalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 1
- -1 C1-3 O-haloalkyl Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003216 pyrazines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se relaciona con pirido{3,2-e]pirazinas, procesos para su preparacion, composiciones farmacéuticas que comprenden dichos compuestos y el uso farmacéutico de dichos compuestos, - los cuales son inhibidores de la fosfodiesterasa 10 - como compuestos activos para tratar desordenes del sistema nervioso central, obesidad y desordenes metabolicos. Reivindicacion 1: Un compuesto de formula (1) caracterizado porque R1 es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cada uno opcionalmente monosustituido o polisustituido con halo, OH, O-alquilo C1-3, ciano o un radical cíclico; arilo, heteroarilo, ciclo(hetero)alquilo C3-8, arilalquilo C1-5, o heteroarilalquilo C1-5, cada uno opcionalmente monosustituido o polisustituido con halo, amino, alquilamino C1-3, dialquilamino C1-3, nitro, alquilo C1-5, O-alquilo C1-3, ciano, haloalquilo C1-3, O-haloalquilo C1-3, COOH, -(C=O)-NR6R7, SO2NR6R7, un radical cíclico, o ciclo(hetero)alquilo C3-8, o dos grupos O-alquilo C1-3 adyacentes, junto a los átomos a los cuales están unidos, forman un grupo cicloheteroarilo de 5 a 7 miembros; R2 es alquilo C1-8, ciclo(hetero)alquilo C3-8, arilalquilo C1-5, o heteroarilalquilo C1-5, cada uno opcionalmente monosustituido o polisustituido con halo, OH, O-alquilo C1-3, o un radical cíclico; R3 es ciano; alquilo C1-8, haloalquilo C1-8, ciclo(hetero)alquilo C3-8, arilalquilo C1-5, heteroarilalquilo C1-5, cada uno opcionalmente monosustituido o polisustituido con halo, OH, O-alquilo C1-3, o un radical cíclico; -NR6R7, (CO)OR6, (CO)NR6R7, NR5(CO)OR6, NR5(C=O)NR6R7, o NR5(SO2R6), en donde R5, R6, y R7 son seleccionados independientemente entre H, un radical cíclico, alquilo C1-8, O-alquilo C1-5, cicloalquilo C3-6, arilalquilo C1-5, heteroarilalquilo C1-5, en donde alquilo C1-8, O-alquilo C1-5, cicloalquilo C3-6, arilalquilo C1-5, y heteroarilalquilo C1-5 son opcionalmente monosustituidos o polisustituidos con halo, OH, O-alquilo C1-3, o un radical cíclico; o bien R6 y R7, junto al átomo de nitrogeno al cual están unidos, forman un grupo cicloheteroalquilo de 4 a 7 miembros; y R4 es halo, R8, o OR8, en donde R8 es H, alquilo C1-8 o ciclo(hetero)alquilo C3-8, cada uno opcionalmente monosustituido o polisustituido con halo, OH, O-alquilo C1-3, o un radical cíclico; arilo C1-5 o heteroarilalquilo C1-5, cada uno opcionalmente monosustituido o polisustituido con halo, amino, alquilamino C1-3, dialquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3, o un radical cíclico; o un N-oxido del mismo, o una sal farmacéuticamente aceptable del mismo.This is related to pyrido {3,2-e] pyrazines, processes for their preparation, pharmaceutical compositions comprising said compounds and the pharmaceutical use of said compounds, - which are phosphodiesterase 10 inhibitors - as active compounds for treating disorders. of the central nervous system, obesity and metabolic disorders. Claim 1: A compound of formula (1) characterized in that R 1 is C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, each optionally monosubstituted or polysubstituted with halo, OH, C 1-3 alkyl, cyano or a cyclic radical; aryl, heteroaryl, cyclo (hetero) C3-8 alkyl, C1-5 arylalkyl, or C1-5 heteroarylalkyl, each optionally monosubstituted or polysubstituted with halo, amino, C1-3 alkylamino, C1-3 dialkylamino, nitro, C1- alkyl 5, C1-3 O-alkyl, cyano, C1-3 haloalkyl, C1-3 O-haloalkyl, COOH, - (C = O) -NR6R7, SO2NR6R7, a cyclic radical, or cyclo (hetero) C3-8 alkyl, or two adjacent C1-3 alkyl groups, together with the atoms to which they are attached, form a 5- to 7-membered cycloheteroaryl group; R2 is C1-8 alkyl, cyclo (hetero) C3-8 alkyl, C1-5 arylalkyl, or C1-5 heteroarylalkyl, each optionally monosubstituted or polysubstituted with halo, OH, O-C1-3 alkyl, or a cyclic radical; R3 is cyano; C1-8 alkyl, C1-8 haloalkyl, cyclo (hetero) C3-8 alkyl, C1-5 arylalkyl, C1-5 heteroarylalkyl, each optionally monosubstituted or polysubstituted with halo, OH, O-C1-3 alkyl, or a radical cyclic; -NR6R7, (CO) OR6, (CO) NR6R7, NR5 (CO) OR6, NR5 (C = O) NR6R7, or NR5 (SO2R6), where R5, R6, and R7 are independently selected from H, a cyclic radical , C1-8 alkyl, O-C1-5 alkyl, C3-6 cycloalkyl, C1-5 arylalkyl, C1-5 heteroarylalkyl, wherein C1-8 alkyl, O-C1-5 alkyl, C3-6 cycloalkyl, C1- arylalkyl 5, and C1-5 heteroarylalkyl are optionally monosubstituted or polysubstituted with halo, OH, O-C1-3 alkyl, or a cyclic radical; or R6 and R7, together with the nitrogen atom to which they are attached, form a 4- to 7-membered cycloheteroalkyl group; and R4 is halo, R8, or OR8, wherein R8 is H, C1-8 alkyl or cyclo (hetero) C3-8 alkyl, each optionally monosubstituted or polysubstituted with halo, OH, O-C1-3 alkyl, or a cyclic radical; C1-5 aryl or C1-5 heteroarylalkyl, each optionally monosubstituted or polysubstituted with halo, amino, C1-3 alkylamino, C1-3 dialkylamino, nitro, C1-3 alkyl, O-C1-3 alkyl, or a cyclic radical; or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US495407P | 2007-11-30 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069509A1 true AR069509A1 (en) | 2010-01-27 |
Family
ID=40342559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105222A AR069509A1 (en) | 2007-11-30 | 2008-11-28 | PIRIDO (3,2-E) PIRAZINAS, ITS PREPARATION AND USE PROCEDURE AS PHOSPHODESTERASE INHIBITORS 10 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090143361A1 (en) |
| AR (1) | AR069509A1 (en) |
| CL (1) | CL2008003577A1 (en) |
| PE (1) | PE20091056A1 (en) |
| TW (1) | TW200927119A (en) |
| WO (1) | WO2009070583A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2010126622A (en) * | 2007-11-30 | 2012-01-10 | УАЙТ ЭлЭлСи (US) | IMIDAZO [1, 5-A] PYRASINES CONDENSED WITH Aryl and Heteroaryl as Pyrophosphodiesterase Inhibitors 10 |
| TW201206935A (en) * | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013034761A1 (en) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
| RU2014123352A (en) | 2011-11-09 | 2015-12-20 | Эббви Дойчланд Гмбх Унд Ко. Кг | HETEROCYCLIC CARBOXAMIDES USEFUL AS PHOSPHODESTERASE TYPE 10A INHIBITORS |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| US9266881B2 (en) | 2011-11-14 | 2016-02-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone PDE10 inhibitors |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| EP2895489B1 (en) | 2012-09-17 | 2017-10-18 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| CN102879517A (en) * | 2012-10-08 | 2013-01-16 | 葵花药业集团(衡水)得菲尔有限公司 | Quality testing method for compound paracetamol and amantadine hydrochloride granules |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| CA2902655A1 (en) | 2013-03-14 | 2014-09-18 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN104177296B (en) * | 2014-08-11 | 2017-01-11 | 蒋军荣 | Preparation method of 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1H-imidazole-5-carboxylic acid ethyl ester |
| EP3856185A1 (en) | 2018-09-28 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| CN111592495A (en) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | A kind of preparation method of 2-n-butyl-4-chloro-5 formyl imidazole |
| CN115137717A (en) * | 2022-06-08 | 2022-10-04 | 深圳先进技术研究院 | Application of disulfiram medicament in treating osteoarthritis |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| AU756838B2 (en) * | 1998-03-04 | 2003-01-23 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| WO2000043392A2 (en) * | 1999-01-20 | 2000-07-27 | Arzneimittelwerk Dresden Gmbh | Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments |
| CN1161341C (en) * | 1999-03-22 | 2004-08-11 | 布里斯托尔-迈尔斯斯奎布公司 | Fused pydiopyridazine inhibitors of cGMP phosphodiesterase |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| ES2249384T3 (en) * | 2000-12-12 | 2006-04-01 | Neurogen Corporation | ESPIRO (ISOBENZOFURAN-1,4'-PIPERADIN) -3-ONAS AND 3H-ESPIROBENZOFURAN-1,4-PIPERIDINAS. |
| US6924291B2 (en) * | 2001-01-23 | 2005-08-02 | Merck & Co., Inc. | Process for making spiro isobenzofuranone compounds |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| CA2534432A1 (en) * | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| ES2326337T3 (en) * | 2005-01-12 | 2009-10-07 | Nycomed Gmbh | NEW PIRROLODIHYDROISOQUINOLINS AS PDE INHIBITORS10. |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| RU2010126622A (en) * | 2007-11-30 | 2012-01-10 | УАЙТ ЭлЭлСи (US) | IMIDAZO [1, 5-A] PYRASINES CONDENSED WITH Aryl and Heteroaryl as Pyrophosphodiesterase Inhibitors 10 |
-
2008
- 2008-11-25 US US12/277,961 patent/US20090143361A1/en not_active Abandoned
- 2008-11-25 WO PCT/US2008/084688 patent/WO2009070583A1/en not_active Ceased
- 2008-11-27 TW TW097145945A patent/TW200927119A/en unknown
- 2008-11-28 CL CL2008003577A patent/CL2008003577A1/en unknown
- 2008-11-28 AR ARP080105222A patent/AR069509A1/en unknown
- 2008-12-01 PE PE2008002004A patent/PE20091056A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090143361A1 (en) | 2009-06-04 |
| PE20091056A1 (en) | 2009-08-20 |
| CL2008003577A1 (en) | 2009-11-27 |
| WO2009070583A1 (en) | 2009-06-04 |
| TW200927119A (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069509A1 (en) | PIRIDO (3,2-E) PIRAZINAS, ITS PREPARATION AND USE PROCEDURE AS PHOSPHODESTERASE INHIBITORS 10 | |
| AR085960A1 (en) | 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2 | |
| AR064608A1 (en) | SUBSTITUTED PIRAZOLO-QUINAZOLINA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. PROCESS FOR THE PREPARATION AND USE OF THE SAME AS ANTICANCER AGENTS. | |
| BR112015015812A2 (en) | pyridine or pyrrole fused pyrimidine derivatives as painkiller autotaxin inhibitors | |
| AR054560A1 (en) | SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AR081577A1 (en) | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
| AR063912A1 (en) | DERIVATIVES OF 1,2,4 OXADIAZOL. PHARMACEUTICAL COMPOSITIONS. | |
| AR077328A1 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| AR086319A1 (en) | FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS | |
| AR084849A1 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| AR062503A1 (en) | PIRIDO DERIVATIVES [2, 3-D] PIRIMIDINE AND PIRAZIN [2, 3-D] PIRIMIDINE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATION BY THE INHIBITION OF MOTOR. | |
| AR081587A1 (en) | DERIVATIVES OF 5,6-DIHIDRO-2H- [1,4] OXAZIN-3-IL-AMINE USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | |
| AR074435A1 (en) | DERIVATIVES OF 1,3-BENZOTIAZOL, DRUGS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF CANCER. | |
| CO6382126A2 (en) | FUSIONED AND ESPIROCICLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| AR043434A1 (en) | PIPERIZACINE DERIVATIVES ACILATED AS AGELISTS OF THE RECEIVER OF MELANOCORTINA-4. PHARMACEUTICAL COMPOSITIONS AND USES | |
| CO6251251A2 (en) | DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | |
| AR054186A1 (en) | DERIVATIVES OF TETRAHYDROINDAZOLONA AND TETRAHYDROINDOLONE | |
| AR044116A1 (en) | COMPOUNDS DERIVED FROM 5,7 DIAMINO PIRAZOLO [4,3-D] PYRIMIDINES, INTERMEDIARIES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE FOR THE MANUFACTURE OF MEDICATIONS | |
| AR066562A1 (en) | CONDENSED PIRROL DERIVATIVES; A PHARMACEUTICAL FORMULATION BASED ON THE COMPOUND AND ITS USE TO PREPARE MEDICINES | |
| AR085406A1 (en) | N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTERIDINONES | |
| AR079205A1 (en) | MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7 | |
| AR074306A1 (en) | AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
| AR084553A1 (en) | HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER | |
| AR065811A1 (en) | DERIVATIVES OF 2-AMINO-4H-IMIDAZOL-4-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |